

**Disclosure of Relevant Financial or Non-financial/Strategic Business Relationships or Partnerships**  
**The American Society of Breast Surgeons**  
**Question of the Week Program**

The Society is charged with ensuring its CME activities are balanced, independent, objective, and scientifically rigorous, through, but not limited to, by identifying and mitigating relevant financial relationships or non-financial/strategic business relationships or partnerships (relationships) between individuals in control of educational content and ineligible companies. By identifying and mitigating relevant relationships, we work together to create a protected space to learn, teach, and engage in scientific discourse free from influence from individuals that may have an incentive to insert commercial bias into a CME activity.

As a CME provider accredited by the [Accreditation Council for Continuing Medical Education \(ACCME\)](#), the ASBrS requires individuals in control of the educational content of a CME activity (including but not limited to, authors, content reviewers, editors, education-based committees, and ASBrS staff) to disclose all financial and non-financial/strategic business relationships or partnerships (relationships) with ACCME-defined ineligible company, within the 24 months prior to their involvement with the CME activity. An ineligible company is a company whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. Please review the following examples at <https://accme.org/rule/eligibility/>.

Individuals in control of educational content must review and adhere to the '[ASBrS CME Activity Disclosure Policy](#)' as well as complete the applicable ASBrS Disclosure Form at the time they are invited to participate in a CME activity. ASBrS committee members (volunteers) are also required to review and adhere to the '[ASBrS Volunteer Conflict of Interest Policy](#)'. Participation is not confirmed without the completion of the disclosure form and will be contingent upon mitigation, if necessary.

Owners or employees of ineligible companies are excluded from controlling content or participating as planners or faculty in a CME activity. The **owners** and **employees** of ineligible companies are considered to have unresolvable financial relationships and must be excluded from participating as planners or faculty and must not be allowed to influence or control any aspect of the planning, delivery, or evaluation of accredited continuing education.

There are three exceptions to this exclusion—owners or employees of ineligible companies can participate as planners or faculty in these specific situations:

- a. When the content of the activity is not related to the business lines or products of their employer/company.
- b. When the content of the accredited activity is limited to basic science research, such as pre-clinical research and drug discovery, or the methodologies of research, and they do not make care recommendations.
- c. When they are participating as technicians to teach the safe and proper use of medical devices, and do not recommend whether or when a device is used.

To assist all CME planners and contributors in identifying relevant relationships, ASBrS staff provides a sample list of typical relevant relationships and possible methods for mitigation—as well as examples of non-compliant actions. However, this list is not an exhaustive list of all scenarios. Participants are required to disclose all possible competing interests, both financial and non-financial, that could interfere with, or could reasonably be perceived as interfering with, their ability to provide objective and valuable contributions to the ASBrS CME activity. All identified relevant relationships are mitigated prior to the education activity being delivered to learners per ACCME Standards for Integrity and Independence in Accredited Continuing Education. The

inability to mitigate an identified relevant relationship results in the participant's withdrawal from participation in the CME activity. A list of disclosures from all CME planners and contributors, as well as all potential and actual mitigation methods (including any instances of non-compliance), are documented and maintained by ASBrS staff. This list is made available to all CME activity planners.

The non-compliance process is initiated when an individual's (in control of educational content of the CME activity) *undisclosed* relationship(s) with an ineligible company is identified or reported during or after the CME activity. The Board of Directors, CME Committee, Ethics Committee, and applicable committee chair(s) will discuss the act of noncompliance and agree upon a resolution.

### ***Oversight***

The CME Committee and Ethics Committees ensure that there is no commercial bias or influence in ASBrS CME activities. They work together to ensure proper conflict management. Members of these committees serve as additional oversight, participating and observing ASBrS CME activities to look for any evidence of bias and ensure compliance with the ASBrS policies.

### ***Reporting Conflicts***

Participants of any ASBrS CME activity may report any improprieties on the applicable evaluation form and to the CME and Ethics Committee at [cme@breastsurgeons.org](mailto:cme@breastsurgeons.org).

Please note we have advised authors it is their responsibility to also disclose if they will be describing the use of a device, product, or drug that is not FDA approved or the off-label use of an approved device, product, or drug or unapproved usage.

**The following individuals and groups have been involved in the planning, content submission, review, mitigation, implementation, approval, evaluation, and/or oversight of the Question of the Week program.**

**All disclosed relationships are within the 24 months prior to their involvement with the CME activity. All relevant disclosed relationships have been mitigated by a CME Committee Official.**

<b>Name of Individual</b>	<b>Individual's Role(s) in Activity (e.g. Planner, Reviewer, Speaker, Author, Moderator, Panelist)</b>	<b>Name of Ineligible Company(s)</b>	<b>Nature of Relevant Financial Relationship(s)</b>	<b>Mechanism(s) Implemented to Mitigate Relevant Financial Relationships Appropriate to Role(s) in the Activity</b>
Sara Javid, MD	Planner, Author, Content Reviewer, Approver (Chair, Question of the Week Committee)	None	N/A	N/A
Candice Sauder, MD	Planner, Author, Content Reviewer, Approver (Vice-Chair, Question of the Week Committee)	None	N/A	N/A
Hira Abidi, MD	Author, Content Reviewer (Question of the Week Committee Member)	None	N/A	N/A
Fatih Aydogan, MD	Author, Content Reviewer (Question of the Week Committee Member)	None	N/A	N/A
Christa Balanoff, MD	Author, Content Reviewer (Question of the Week Committee Member)	None	N/A	N/A
Mary Legenza, MD	Author, Content Reviewer (Question of the Week Committee Member)	None	N/A	N/A
Aye Moe Thu Ma, MD	Author, Content Reviewer (Question of the Week Committee Member)	None	N/A	N/A
Emily Marcinkowski, MD	Author, Content Reviewer (Question of the Week Committee Member)	None	N/A	N/A
Faina Nakhlis, MD	Author, Content Reviewer (Question of the Week Committee Member)	None	N/A	N/A
Lauren Perry, MD	Author, Content Reviewer (Question of the Week Committee Member)	None	N/A	N/A

Kristina Shaffer, MD	Author, Content Reviewer (Question of the Week Committee Member)	None	N/A	N/A
Austin Williams, MD	Author, Content Reviewer (Question of the Week Committee Member)	None	N/A	N/A
Sarah McLaughlin, MD	Regulatory, Program Reviewer (Chair, CME Committee)	None	N/A	N/A
Kjirsten Carlson, MD	Regulatory, Program Reviewer (CME Committee)	None	N/A	N/A
Meghan Flanagan, MD, MPH	Regulatory, Program Reviewer (CME Committee)	None	N/A	N/A
Janie Gia-Lin Grumley, MD	Regulatory, Program Reviewer (CME Committee)	None	N/A	N/A
Jillian Lloyd, MD	Regulatory, Program Reviewer (Vice-Chair, CME Committee)	None	N/A	N/A
Ranjna Sharma, MD	Regulatory, Program Reviewer (CME Committee)	None	N/A	N/A
Jennifer Gass, MD	Regulatory, Program Reviewer (CME Committee)	None	N/A	N/A
Micheal Berry, MD	Program Approver (Board of Directors)	Astrazeneca; TransMed7 (relationship ended)	Speaker, Honoraria; Owner	The Board of Directors guide the Society's strategic direction by approving all ASBrS educational activities. As a board of director member, Dr. Berry recused himself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).
Susan Boolbol, MD	Program Approver (Board of Directors)	Peace Medical Consultants, LLC	Honorarium; Executive role (Owner)	The Board of Directors guide the Society's strategic direction by approving all ASBrS educational activities.

				As a board of director member, Dr. Boolbol recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).
Judy Boughey, MD	Program Approver (Board of Directors)	None	N/A	N/A
David Brenin, MD	Program Approver (Board of Directors)	None	N/A	N/A
Jill Dietz, MD	Program Approver (Board of Directors)	Peace Medical Consultants, LLC; Cyduct DX	Honorarium, expenses, consulting fees, Co-Owner; Options, Chief Medical Officer (Ownership Interest, Employee)	The Board of Directors guide the Society's strategic direction by approving all ASBrS educational activities. As a board of director member, Dr. Dietz recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).
Regina Hampton, MD	Program Approver (Board of Directors)	Cherry Blossom Intimates, Inc.	Owner	The Board of Directors guide the Society's strategic direction by approving all ASBrS educational activities. As a board of director member, Dr. Hampton recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).
Ronda Henry-Tillman, MD	Program Approver (Board of Directors)	None	N/A	N/A

Kevin Hughes	Program Approver (Board of Directors)	Hologic; TME; Invitae; AstraZeneca	Honoraria/Consulting Fees; Honoraria/Consulting Fees; Honoraria/Consulting Fees; Honoraria/Consulting Fees	The Board of Directors guide the Society's strategic direction by approving all ASBrS educational activities. As a board of director member, Dr. Hughes recused himself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).
Brigid Killelea, MD	Program Approver (Board of Directors)	EndoMag; UptoDate	Travel expenses, Consultant; Royalties, Author	The Board of Directors guide the Society's strategic direction by approving all ASBrS educational activities. As a board of director member, Dr. Killelea recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).
Eric Manahan, MD	Program Approver (Board of Directors)	AstraZeneca; TME; Endomag; Elucent; Myriad Genetics	Honoraria, Speaker; Honoraria, Speaker; Honoraria, Speaker; Honoraria, Speaker	The Board of Directors guide the Society's strategic direction by approving all ASBrS educational activities. As a board of director member, Dr. Manahan recused himself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).
Toan Nguyen, MD	Program Approver (Board of Directors)	Aptitude Health	Honorarium; Consultant/Advisor	The Board of Directors guide the Society's strategic direction by approving all ASBrS educational activities. As a board of director member, Dr. Nguyen recused himself from

				discussions and decisions where a conflict of interest could occur related to their financial relationship(s).
Puneet Singh, MD	Oversight (Ethics Committee)	None	N/A	N/A
Jennifer Tseng, MD	Oversight (Ethics Committee)	Intuitive Surgical	Site Principal Investigator	As an Ethics committee member, Dr. Singh recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship(s).
Cindy Matsen, MD, MSCI, FACS	Oversight (Ethics Committee)	None	N/A	N/A
Tina Hieken, MD	Oversight (Ethics Committee)	Genentech; SkylineDX BV	Research Funding (Institution); Research Funding (Institution)	As an Ethics committee member, Dr. Hieken recused herself from discussions and decisions where a conflict of interest could occur related to their financial relationship
Lisa Allen, MD	Oversight (Ethics Committee)	None	N/A	N/A
Katherina Zabicki Calvillo, MD	Oversight (Ethics Committee)	None	N/A	N/A
Jennifer H. Fieber, MD	Oversight (Ethics Committee)	None	N/A	N/A
Stephanie Serres, MD, PhD	Oversight (Ethics Committee)	None	N/A	N/A
Erica Holland (Executive Director)	ASBrS Staff	None	N/A	N/A
Tekoah White (Education Manager)	ASBrS Staff	None	N/A	N/A
Patricia Lovell (Education Assistant)	ASBrS Staff	None	N/A	N/A